- Home
- OPAD vs CVM Comparison
OPAD vs CVM Comparison
Compare OPAD & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPAD | CVM |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | United States | United States |
| Employees | 140 | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 32.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | OPAD | CVM |
|---|---|---|
| Price | $0.80 | $3.19 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.83 | N/A |
| AVG Volume (30 Days) | ★ 676.1K | 58.5K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.57 | $0.23 |
| 52 Week High | $6.35 | $13.48 |
Technical Indicators
Market Signals| Indicator | OPAD | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 38.36 |
| Support Level | $0.70 | $3.18 |
| Resistance Level | $0.90 | $4.84 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 63.55 | 3.89 |
Price Performance
Historical ComparisonAbout OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.